ECSP10010224A - Formulaciones líquidas de hormona luteinizante (lh). - Google Patents

Formulaciones líquidas de hormona luteinizante (lh).

Info

Publication number
ECSP10010224A
ECSP10010224A EC2010010224A ECSP10010224A ECSP10010224A EC SP10010224 A ECSP10010224 A EC SP10010224A EC 2010010224 A EC2010010224 A EC 2010010224A EC SP10010224 A ECSP10010224 A EC SP10010224A EC SP10010224 A ECSP10010224 A EC SP10010224A
Authority
EC
Ecuador
Prior art keywords
luteinizing hormone
liquid formulations
hormone liquid
administration
luteinizing
Prior art date
Application number
EC2010010224A
Other languages
English (en)
Spanish (es)
Inventor
Rita Agostinetto
Fabrizio Samaritani
Rio Alessandra Del
Joel Richard
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of ECSP10010224A publication Critical patent/ECSP10010224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EC2010010224A 2007-11-01 2010-05-31 Formulaciones líquidas de hormona luteinizante (lh). ECSP10010224A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
US448107P 2007-11-28 2007-11-28

Publications (1)

Publication Number Publication Date
ECSP10010224A true ECSP10010224A (es) 2010-07-30

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010224A ECSP10010224A (es) 2007-11-01 2010-05-31 Formulaciones líquidas de hormona luteinizante (lh).

Country Status (25)

Country Link
US (1) US8664369B2 (https=)
EP (1) EP2219607B1 (https=)
JP (1) JP5551601B2 (https=)
KR (1) KR101513181B1 (https=)
CN (1) CN101842083B (https=)
AU (1) AU2008320844B2 (https=)
BR (1) BRPI0818324B8 (https=)
CA (1) CA2700662C (https=)
CY (1) CY1113121T1 (https=)
DK (1) DK2219607T3 (https=)
EA (1) EA019432B1 (https=)
EC (1) ECSP10010224A (https=)
ES (1) ES2393233T3 (https=)
HR (1) HRP20120660T1 (https=)
IL (1) IL205105A (https=)
MX (1) MX2010004639A (https=)
MY (1) MY153976A (https=)
NZ (1) NZ583991A (https=)
PL (1) PL2219607T3 (https=)
PT (1) PT2219607E (https=)
RS (1) RS52566B (https=)
SI (1) SI2219607T1 (https=)
UA (1) UA101484C2 (https=)
WO (1) WO2009056569A1 (https=)
ZA (1) ZA201001907B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2016505601A (ja) * 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN1309567A (zh) * 1998-07-23 2001-08-22 伊莱利利公司 Fsh和fsh变体制剂,产品和方法
DE602004019761D1 (de) * 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US7387998B2 (en) 2003-03-28 2008-06-17 New York University STQ peptides
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Also Published As

Publication number Publication date
EA019432B1 (ru) 2014-03-31
HRP20120660T1 (hr) 2012-09-30
AU2008320844A1 (en) 2009-05-07
ZA201001907B (en) 2011-05-25
JP5551601B2 (ja) 2014-07-16
KR101513181B1 (ko) 2015-04-21
BRPI0818324B1 (pt) 2019-12-24
KR20100088147A (ko) 2010-08-06
CA2700662C (en) 2015-10-13
CA2700662A1 (en) 2009-05-07
EP2219607B1 (en) 2012-08-15
RS52566B (sr) 2013-04-30
ES2393233T3 (es) 2012-12-19
IL205105A0 (en) 2010-11-30
UA101484C2 (en) 2013-04-10
MX2010004639A (es) 2010-08-04
SI2219607T1 (sl) 2012-09-28
US20100261649A1 (en) 2010-10-14
NZ583991A (en) 2012-02-24
US8664369B2 (en) 2014-03-04
WO2009056569A1 (en) 2009-05-07
BRPI0818324A2 (pt) 2017-05-16
MY153976A (en) 2015-04-30
HK1145443A1 (en) 2011-04-21
PT2219607E (pt) 2012-08-31
EP2219607A1 (en) 2010-08-25
IL205105A (en) 2015-04-30
JP2011502968A (ja) 2011-01-27
CY1113121T1 (el) 2016-04-13
DK2219607T3 (da) 2013-06-17
AU2008320844B2 (en) 2013-08-29
PL2219607T3 (pl) 2012-12-31
CN101842083B (zh) 2012-11-14
CN101842083A (zh) 2010-09-22
EA201070549A1 (ru) 2010-10-29
WO2009056569A9 (en) 2010-01-21
BRPI0818324B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
BR112016000194A8 (pt) forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
EA201391689A1 (ru) Система доставки лекарственного средства
PE20090607A1 (es) Formulacion farmaceutica de dispersion liposomal en polvo seco
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
EA201170512A1 (ru) Композиция для перорального введения
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
EP3784214C0 (en) ORAL LIQUID PHARMACEUTICAL DOSAGE FORM
TN2015000135A1 (en) Modified release formulations for oprozomib
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
ECSP088850A (es) Formulación de medicamento líquida
IT1401284B1 (it) Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
ES2325291A1 (es) "uso de un extracto de silybum marianum"
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.